Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | The future of cord blood transplant in leukemia treatment

Filippo Milano • 10 Dec 2023
ASH 2023
Leukemia

Filippo Milano, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the future of cord blood transplant (CBT) in leukemia treatment. Despite the decrease in CBT due to long recovery times and risk of infection, Dr Milano highlights that this therapeutic option still has a future, especially considering its remarkable benefits in high-risk patients. Recent FDA approval of a CBT product may encourage its use in the clinical setting. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Filippo Milano

1:18
UM171 improves outcomes of cord-blood transplants in high-risk leukemia
Filippo Milano • 10 Dec 2023

Related Videos

1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals